[144] Thermo Fisher Scientific, Inc. SEC Filing
Thermo Fisher Scientific (TMO) Rule 144 notice shows an insider proposes to sell 201 shares of common stock through Fidelity Brokerage, with an aggregate market value of $100,533.57 based on the filing.
Rhea-AI Filing Summary
Thermo Fisher Scientific (TMO) Rule 144 notice shows an insider proposes to sell 201 shares of common stock through Fidelity Brokerage, with an aggregate market value of $100,533.57 based on the filing. The shares are reported as acquired via an option granted on 02/26/2019 and exercised/dated 08/19/2025 with cash payment. The filer has aggregated recent dispositions: Marc N. Casper sold 10,000 shares on 08/06/2025 for $4,518,207.00 and 8,000 shares on 08/07/2025 for $3,635,549.60. The notice includes the standard insider representation that no material nonpublic information is known.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider plans a small Rule 144 sale after exercising options; significant recent sales by Marc N. Casper are notable for volume and proceeds.
The filing reports a proposed sale of 201 shares valued at $100,533.57, acquired via an option grant dated 02/26/2019 and recorded with an acquisition/exercise date of 08/19/2025. The proposed sale is routed through Fidelity on the NYSE. Recent reported transactions show total proceeds exceeding $8 million from sales of 18,000 shares by Marc N. Casper across two days, indicating meaningful liquidity events by an insider. For investors, the Rule 144 notice itself is routine compliance; the material element is the magnitude of the prior sales which may reflect portfolio diversification or other personal financial planning.
TL;DR: The disclosure follows Rule 144 formality; the representation about absence of material nonpublic information is standard and required.
The form documents acquisition via option and a cash payment on the exercise date, and includes the attestation required under Rule 144. The existence of recent large sales by Marc N. Casper should prompt review of any open-window policies, blackout periods, or 10b5-1 plans, although none are explicitly stated here. The filing contains no indication of restricted transfers or unusual consideration, and it satisfies the regulatory notice of proposed sale requirements.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filed for Thermo Fisher Scientific (TMO) disclose?
Who acted as broker for the proposed sale on Form 144 for TMO?
Have there been recent insider sales by company insiders in this filing?
Does the filing state whether the seller knows any material nonpublic information?
AI-generated analysis. How Rhea-AI works. Not financial advice.